Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681195 · ClinicalTrials.gov registry record · Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
A Phase 2 study of Refractory Cancer and Primary Central Nervous System Lymphoma, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05681195 is a Phase 2 study of Refractory Cancer and Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 15 participants, below the 129-participant average among 15 other Refractory Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05681195, a Phase 2 study of Refractory Cancer and Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Pemetrexed
- PROCEDURE Autologous Stem Cell Transplant (ASCT)
- RADIATION Whole Brain Radiation Therapy (WBRT)
Study Locations (1)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2033-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05681195
The ClinicalTrials.gov registry entry for NCT05681195 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 15 other Refractory Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Cancer appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT05681195 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05681195 about?
NCT05681195 is a clinical study titled "Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas". This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymp...
What is the current status of trial NCT05681195?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-04-25. Estimated completion is 2033-02.
What conditions does trial NCT05681195 study?
This clinical trial studies the following conditions: Refractory Cancer, Primary Central Nervous System Lymphoma, Relapsed Cancer, Secondary Central Nervous System Lymphoma.
What interventions are being tested in trial NCT05681195?
The interventions under investigation include: Zanubrutinib (DRUG), Pemetrexed (DRUG), Autologous Stem Cell Transplant (ASCT) (PROCEDURE), Whole Brain Radiation Therapy (WBRT) (RADIATION).
Who is sponsoring clinical trial NCT05681195?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05681195 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RECRUITING · Phase 2
-
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.